LABQUALITY

External Quality Assessment Scheme

Helicobacter pylori, antibodies 4, 2017

Thank you for your participation in the fourth round as one of the 59 units from 14 countries. Some units returned multiple results/sample.

Test items

The specimens consisted of two human sera, which were shipped in ambient temperature. They were requested to be stored at 2 … 8 °C and analysed within one week. The serum specimens were obtained from patients who had not been treated for *Helicobacter pylori.*

Specimen S001: Cl. interpretation: Active or past infection;
IgG + IgA -

Specimen S002: Cl. interpretation: Active or past infection;
IgG + IgA +/-

Results

The reports for this scheme have been renewed and are now generated in LabScala. The results are divided into groups according to the method stated by the laboratory. Guidelines how to interpret the reports can be found under ”LabScala user instructions” in LabScala.

The qualitative method results and quantitative method results are presented in laboratory method-specific tables. Accepted results are marked with green color and laboratory’s own result with a black radio button (⊙). In the scoring section you can see summaries of overall success rate and sample-specific success rates (%). Sample-specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodics counts in the tables. The cumulative scoring history is calculated according to the order of the results. Therefore we recommend you to locate the results of your primary method to the top of the result form.

Change in the report layout: Please note that by default the distribution pies are closed in the scoring reports. You can open the distribution pies by clicking the screen button at the right end of the result distribution row.

If you have no results you will get a note: “You have not responded in time, only global report is available.”

The participants of this EQA scheme are able to report three (3) results for each specimen in LabScala, if the material is sufficient for additional analysis. This opportunity is intended for different test kits or instruments of one testing unit.

In case you have any questions regarding the reports, please contact the EQA coordinator.

2017-12-22

Final report

Product no. 5860
LQ757617041-042/US
Subcontracting: Sample pretesting

Items sent	2017-11-21
Round closed	2017-12-14
Expected results	2017-12-18
Report released	2017-12-22

The report contains
- Individual result and scoring tables
- Expected results and comments of the expert

Request for corrections
Typing errors in laboratory’s result forms are on laboratory’s responsibility. Labquality accepts responsibility only for result processing.

Requests must be notified by writing within three weeks from the date of this letter.

Expert
Dr. Jukka Hytönen, MD, PhD
University of Turku
Department of Medical Microbiology and Immunology

Authorized by
EQA Coordinator
Tanja Vanhelo
+358 9 8566 8215
tanja.vanhelo@labquality.fi

The next *Helicobacter pylori*, antibodies EQA round 1, 2018 will be carried out in March 2018.

Labquality
Kumpulantie 15
FI-00520 HELSINKI

Telephone
+358 9 8566 8200

Fax
+358 9 8566 8280
+358 9 8566 8281

info@labquality.fi
www.labquality.fi

FINAS
Finnish Accreditation Service
PT02 (EN ISO/IEC 17043)

Evaluation and comments

The last *Helicobacter pylori* antibody round of the year included two antibody positive specimens.

All participating laboratories reported positive IgG results of specimen S001. Consensus was also reached on IgA antibodies, since the majority of participating laboratories reported negative IgA results. All laboratories using qualitative tests reported positive results. As clinical interpretation “Active or past infection” was correct/expected.

Regarding the positive specimen S002, the majority of laboratories using EIA methodology detected IgG *H. pylori* antibodies in the specimen. However, no consensus was reached on IgA antibodies, and thus IgA results were not scored. Four laboratories reported negative IgA results and six laboratories reported positive IgA results. All laboratories using qualitative tests reported positive results. The clear consensus on the clinical interpretation of this sample was “Active or past infection”.

Scores

The round is scored based on test HepyAb, HepyAbA and HepyAbG test results and clinical interpretation. If less than 60% of the participants have reported correct/expected result, the test result/clinical interpretation or the specimen in question will not be scored.

The following general rules are applied:

- Correct/expected test result	2/2 points.
- Partly correct/expected test result	1/2 points.
- Incorrect/deviating test result	0/2 points.
- Correct/expected clinical interpretation	4/4 points.
- Incorrect/deviating clinical interpretation	0/4 points.

Exceptions:
- IgA test results of specimen S002 are not scored.

Laboratory’s scores have been converted to percentage (own success rate, % from maximum scores) with a target at 100%. Own success rate is compared with the success rate of all results.

For laboratories ordering the paper print-out: The laboratory-specific numerical summaries and report letters of this EQA round are available on the **Labquality homepage** (www.labquality.fi). Please log in to **LabScala** on the top of the website and fill in your laboratory’s **client code/personal user name** and **password**. Then please choose **View Reports** under **My EQA** on the front page.

End of report